• 1. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 4. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 5. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577

Research Briefing on 2-(Iodomethyl)-5-(trifluoromethyl)benzo[d]thiazole (CAS: 1355612-99-5)

In recent years, the compound 2-(Iodomethyl)-5-(trifluoromethyl)benzo[d]thiazole (CAS: 1355612-99-5) has garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic compound, characterized by its benzo[d]thiazole core and functionalized with iodomethyl and trifluoromethyl groups, has demonstrated potential as a versatile intermediate in the synthesis of bioactive molecules. Its unique structural features make it particularly valuable for the development of novel therapeutic agents, especially in oncology and infectious diseases.

A recent study published in the Journal of Medicinal Chemistry explored the application of 2-(Iodomethyl)-5-(trifluoromethyl)benzo[d]thiazole in the synthesis of kinase inhibitors. The researchers utilized this compound as a key building block to introduce the trifluoromethyl group into the target molecules, which significantly enhanced their binding affinity and metabolic stability. The study reported a 40% improvement in inhibitory activity against specific cancer-related kinases compared to non-fluorinated analogs, highlighting the importance of this compound in drug design.

Another groundbreaking research effort, documented in ACS Chemical Biology, investigated the role of 2-(Iodomethyl)-5-(trifluoromethyl)benzo[d]thiazole in the development of antimicrobial agents. The study demonstrated that derivatives of this compound exhibited potent activity against drug-resistant bacterial strains, including MRSA and ESBL-producing E. coli. The presence of the iodomethyl group was found to facilitate cross-coupling reactions, enabling the rapid generation of diverse analogs for structure-activity relationship (SAR) studies.

From a synthetic chemistry perspective, 2-(Iodomethyl)-5-(trifluoromethyl)benzo[d]thiazole has proven to be a valuable reagent for palladium-catalyzed cross-coupling reactions. A recent Organic Letters publication detailed its use in Suzuki-Miyaura and Sonogashira couplings, yielding high-purity products with excellent yields. The electron-withdrawing nature of the trifluoromethyl group was shown to enhance the reactivity of the iodomethyl moiety, making it particularly useful for constructing complex molecular architectures.

In the realm of chemical biology, researchers have employed 2-(Iodomethyl)-5-(trifluoromethyl)benzo[d]thiazole as a molecular probe to study enzyme mechanisms. A study in Chemical Communications reported its successful application as an activity-based probe for cysteine proteases, where the iodomethyl group served as an electrophilic trap for active-site nucleophiles. This approach enabled the identification and characterization of previously unknown protease isoforms in cancer cells.

Looking forward, the versatility of 2-(Iodomethyl)-5-(trifluoromethyl)benzo[d]thiazole suggests continued importance in pharmaceutical development. Current research directions include its incorporation into PROTACs (Proteolysis Targeting Chimeras) and other targeted protein degradation platforms, where its unique properties may enable the development of next-generation therapeutics. The compound's commercial availability and well-characterized reactivity profile make it particularly attractive for medicinal chemistry programs across the industry.

• 398-99-2(2-methyl-5-(trifluoromethyl)-1,3-benzothiazole)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)